Brief: Citius Pharma Reports Clinical Collaboration With University Of Pittsburgh
22/09/2022 21:31
Sept 22 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES A CLINICAL COLLABORATION
WITH
THE UNIVERSITY OF PITTSBURGH TO EVALUATE T-REG CELL DEPLETION
WITH I/ONTAK (E7777) IN COMBINATION WITH PEMBROLIZUMAB IN
RECURRENT OR METASTATIC SOLID CANCER TUMORS IN A PHASE 1
INVESTIGATOR-INITIATED TRIAL
* CITIUS PHARMACEUTICALS INC- I/ONTAK PLUS PD-1 CHECKPOINT
INHIBITOR PEMBROLIZUMAB TO BE EVALUATED IN SOLID TUMOR PATIENTS
* CITIUS PHARMACEUTICALS INC- UNIVERSITY OF PITTSBURGH
DOSE-RANGING STUDY EXPECTED TO BEGIN IN Q4 OF 2022
Source text for Eikon: ID:nPn6dsjWRa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules